cvot tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized In patients with type 2
Description
But in the process the doctor will get the history of how the problem develops and the symptoms associated with it
Before you start using Ozempic or Trulicity, be sure to talk with your doctor to see if these warnings apply to you
C., Sierts, M., Egberink, L
Eating cleaner than ever
